InstalabLoading...
InstalabLoading...
An immune protein produced in response to a common virus, signaling whether you have a recent or active cytomegalovirus infection.
If you have ever wondered whether a recent illness, an unexplained fever, or fatigue might be caused by a common but often overlooked virus, CMV IgM (cytomegalovirus immunoglobulin M) can help answer that question. This blood test detects a specific type of antibody your immune system produces early in its response to cytomegalovirus, one of the most widespread viruses in the world. A positive result suggests your body is actively fighting, or has very recently fought, a CMV infection.
That said, this is a test that requires careful interpretation. Your body makes IgM antibodies as a first responder to infection, but they can linger for months after the initial illness, reappear during a flare-up of a dormant infection, and sometimes show up falsely when you actually have a different virus entirely. Understanding what a positive result does and does not tell you is essential before acting on it.
The core challenge with CMV IgM is that a positive result does not always mean what it seems. The positive predictive value, meaning the chance that a positive result actually reflects a true recent infection, varies dramatically depending on the situation. In pregnant women without symptoms, only about 16% of positive CMV IgM results reflect a true primary infection. In pregnant women whose ultrasound shows fetal abnormalities, that number rises to about 37%. Among people hospitalized with symptoms that look like CMV, it is roughly 35%.
False positives are a real concern. If you are infected with Epstein-Barr virus (the virus that causes mono), your CMV IgM test may come back positive even though CMV is not the problem. Immune disorders can also trigger misleading results. And because IgM antibodies can persist for months after a primary infection or reappear during reactivation of dormant virus, a positive result alone cannot tell you exactly when you were first infected.
This is why most clinicians will follow up a positive CMV IgM with a test called IgG avidity. Your body initially makes loosely fitting antibodies (low avidity) against a new threat, then gradually refines them into tightly binding ones (high avidity). If your IgG avidity is low, the infection is likely recent. If it is high, the infection probably happened months ago and the IgM is simply lingering. When a strongly positive IgM result is confirmed by a second method and paired with a high ratio of IgM to IgG, the positive predictive value for infection within the previous three months reaches approximately 91%.
What this means for you: if you get a positive CMV IgM result, do not assume the worst. Ask for IgG avidity testing to clarify timing. The IgM result on its own is a starting point, not a definitive answer.
For most healthy adults, CMV infection is mild or even silent. But for certain groups, knowing your CMV status is genuinely important because the stakes of infection are much higher.
Pregnant women: A first-time CMV infection during pregnancy carries a 30 to 40% risk of transmitting the virus to the fetus. Timing matters enormously. Infections in the first trimester are the most damaging, with 40 to 50% of infected newborns developing neurologic problems including hearing loss, intellectual disability, and seizures. Among infants born with symptomatic congenital CMV, roughly 30% die and 65 to 80% of survivors have severe neurologic consequences. Even babies who appear healthy at birth are not in the clear: 10 to 15% go on to develop hearing loss or developmental delays later in childhood. Congenital CMV is the leading nongenetic cause of childhood hearing loss in the United States.
Transplant recipients: If you are receiving an organ or bone marrow transplant, CMV can cause direct disease such as pneumonia, hepatitis, or gastrointestinal inflammation, as well as indirect effects like increased risk of graft rejection and secondary infections. For transplant screening, doctors typically use CMV IgG (not IgM) before the procedure, and then monitor with direct viral detection methods afterward rather than antibody tests.
People with advanced HIV: Before effective antiretroviral therapy became available, about 30% of people with AIDS developed CMV retinitis, an infection of the eye that can cause blindness. CMV disease in this group typically occurs when immune cell counts (CD4 cells) drop below 50 cells per cubic millimeter.
Premature infants: Babies born early are especially vulnerable. Among mothers of premature infants who carry CMV, 82% shed the virus in breast milk, approximately 15% of exposed infants acquire the infection, and 30% of those develop symptomatic disease.
CMV IgM is rarely used alone to make clinical decisions. Think of it as a screening signal that needs confirmation. The most reliable approach combines IgM with IgG avidity testing. A positive IgM with low avidity points strongly toward a recent primary infection. A positive IgM with high avidity suggests an older infection where the antibodies have simply stuck around.
In certain clinical scenarios, clinicians skip IgM entirely. Post-transplant CMV monitoring relies on quantitative nucleic acid testing, which directly measures viral DNA in the blood rather than relying on antibody responses that can be unreliable when the immune system is suppressed. Pre-transplant screening uses IgG to determine whether a donor or recipient has ever been exposed to CMV.
One common source of confusion arises when both CMV IgM and EBV IgM come back positive at the same time. This dual positivity is surprisingly common in hospitalized adults with acute illness and can make it difficult to determine which virus is actually responsible for symptoms. If you find yourself in this situation, additional testing and clinical context are needed to sort out the true cause.
Certain lab factors can occasionally affect IgM results, so if a result seems inconsistent with your clinical picture, confirmatory testing with a different method is reasonable.
CMV IgM is not a biomarker you try to raise or lower through lifestyle changes. It reflects your immune system's response to an active or recent viral infection. Your IgM level will naturally rise after a primary CMV infection and typically decline over weeks to months, though it can persist longer in some individuals.
The main factors that influence whether CMV IgM appears or reappears are those that affect the virus itself or your immune system's ability to keep it in check. Immunosuppressive medications used in transplant recipients can allow dormant CMV to reactivate, which may trigger a new IgM response. Advanced HIV with severely depleted immune cells can similarly permit CMV reactivation and disease. Effective antiretroviral therapy for HIV and careful management of immunosuppression in transplant patients are the primary strategies for preventing CMV reactivation in those populations.
For pregnant women concerned about primary infection, the most practical intervention is prevention. CMV spreads through close contact with body fluids, particularly from young children. If you are pregnant or planning pregnancy and have not previously been infected, careful hygiene around toddlers, including handwashing after diaper changes and avoiding sharing utensils, is the most evidence-supported protective measure.